Antithrombin III Prevents Renal Dysfunction and Hypertension Induced by Enhanced Intravascular Coagulation in Pregnant Rats: Pharmacological Confirmation of the Benefits of Treatment with Antithrombin III in Preeclampsia

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 5, 1996, Pages 702-711

  Shinyama, Hiroshi ^a   Akira, Toshiaki ^a   Uchida, Takeshi ^a   Hirahara, Keizo ^b   Watanabe, Masahiro ^a   Kagitani, Yoshio ^a  

^a Green Cross Company   (South Korea)

^b Pharmaceutical Devmt Res Lab   (Japan)

Author keywords

Antithrombin III; Coagulation; Hemodynamics; Hypertension; Preeclampsia; Proteinuria

Indexed keywords

ANTITHROMBIN III; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; FEMALE; FIBRIN DEPOSITION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY DISEASE; MATERNAL HYPERTENSION; NONHUMAN; PLASMA RENIN ACTIVITY; PREECLAMPSIA; PREGNANCY COMPLICATION; PRIORITY JOURNAL; PROPHYLAXIS; RAT;

ANIMALS; ANTITHROMBIN III; BLOOD COAGULATION; FEMALE; FIBRIN; HYPERTENSION; KIDNEY; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; PROTEINURIA; RATS; RATS, WISTAR; REGIONAL BLOOD FLOW; RENIN; SERUM ALBUMIN; THROMBOPLASTIN;

EID: 0029863714     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199605000-00013     Document Type: Article

References (45)

1. Friedman SA, Taylor RN, Roberts JM. Pathophysiology of preeclampsia. Clin Perinatol 1991;18:661-82.
2. de Groot CJM, Taylor RN. New insights into the etiology of preeclampsia. Ann Med 1993;25:243-9.
3. Zeeman GG, Dekker GA. Pathogenesis of preeclampsia: a hypothesis. Clin Obstet Gynecol 1992;35:317-37.
4. Weiner CP, Brandt J. Plasma antithrombin III activity: an aid in the diagnosis of preeclampsia-eclampsia. Am J Obstet Gynecol 1982; 142:275-81.
5. Weenink GH, Treffers PE, Vijn P, Smorenberg-Schoorl ME, Cate JWT. Antithrombin III levels in preeclampsia correlate with maternal and fetal morbidity. Am J Obstet Gynecol 1984;148:1092-7.
6. Kobayashi T, Terao T. Preeclampsia as chronic disseminated intravascular coagulation. Gynecol Obstet Invent 1987;24:170-8.
7. de Boer K, ten Cate JW, Sturk A, Borm JJJ, Treffers PE. Enhanced thrombin generation in normal and hypertensive pregnancy. Am J Obstet Gynecol 1989;160:95-100.
8. Weiner CP. Preeclampsia-eclampsia syndrome and coagulation. Clin Perinatol 1991;18:713-26.
9. Perry KG Jr, Martin JN Jr. Abnormal hemostasis and coagulopathy in preeclampsia and eclampsia. Clin Obstet Gynecol 1992;35:338-50.
10. Terao T, Maki M, Ikenoue T, et al. The relationship between clinical signs and hypercoagulable state in toxemia of pregnancy. Gynecol Obstet Invest 1991;31:74-85.
11. Cadroy Y, Grandjean H, Pichon J, et al. Evaluation of six markers of haemostatic system in normal pregnancy and pregnancy complicated by hypertension or pre-eclampsia. Br J Obstet Gynaecol 1993;100:416-20.
12. McKay DG. Chronic intravascular coagulation in normal pregnancy and preeclampsia. Contr Nephrol 1981;25:108-19.
13. Page EW. On the pathogenesis of pre-eclampsia and eclampsia. J Obstet Gynaecol Br Commonwealth 1972;79:883-94.
14. Pitlik JR, Nemerson Y. Purification and characterization of tissue factor apoprotein. Methods Enzymol 1978;45:37-48.
15. Walker JJ. Hypertension in pregnancy. Br J Obstet Gynaecol 1994; 101:639-44.
16. Gallus AS, Hirsh J. Antithrombotic drugs: part I. Drugs 1976;12: 41-68.
17. Lechner K, Kyrle PA. Antithrombin III concentrates - are they clinically useful? Thromb Haemost 1995;73:340-8.
18. Bonnar J, Sheppard BL. Coagulation activation and local vascular changes in preeclampsia. Contr Nephrol 1981;25:98-107.
19. Weiner CP, Bonsib SM. Relationship between renal histology and plasma antithrombin III activity in women with early onset preeclampsia. Am J Perinatol 1990;7:139-43.
20. Ohno H, Kambayashi J, Chang SW, Kosaki G. FOY: [Ethyl p-(6 guanidinohexanoyloxy) benzoate] methanesulfonate as a serine protease inhibitor. II. In vitro effect on coagulofibrinolytic system in comparison with heparin or aprotinin. Thromb Res 1981;24: 445-52.
21. Collen D, Schetz J, De Cock F, Holmer E, Verstraete M. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and heparin administration. Eur J Clin Invest 1977;7:27-35.
22. Shinyama H, Nagai H, Kawamura T, et al. Protective effects of AE0047, a novel calcium antagonist, on incidence of stroke and hemodynamic disturbances in stroke-prone spontaneously hypertensive rats. J Pharmacol Exp Ther 1995;272:911-9.
23. Osborn JL, DiBona GF, Thames MD. Role of renal α-adrenoceptors mediating renin secretion. Am J Physiol 1982;242:F620-6.
24. de Jong CLD, Dekker GA, Sibai BM. The renin-angiotensin-aldosterone system in preeclampsia, a review. Clin Perinatol 1991; 18:683-711.
25. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res 1994;74:1-23.
26. Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of haemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980;255:10081-90.
27. Kawasaki H, Hayashi K, Awai M. Disseminated intravascular coagulation (DIC): immunohistochemical study of fibrin-related materials (FRMs) in renal tissues. Acta Pathol Jpn 1987;37:77-84.
28. Lindheimer MD, Katz AI. Renal physiology and disease in pregnancy. In: Seldin DW, Giebisch G, eds. The kidney: physiology and pathophysiology, 2nd ed. New York: Raven Press, 1992:3371-431.
29. Rosenberg RD. Actions and interactions of antithrombin and heparin. N Engl J Med 1975;13:146-51.
30. Björk I, Olson ST, Shore JD. Molecular mechanisms of the accelerating effect of heparin on the reactions between antithrombin and clotting proteinases. In: Lane DA. Lindahl U, eds. Heparin. London: Edward Arnold, 1989:229-55.
31. Carlström A-S, Liedén K, Björk I. Decreased binding of heparin to antithrombin following the interaction between antithrombin and thrombin. Thromb Res 1977;11:785-97.
32. Jesty J. The inhibition of activated bovine coagulation factors X and VII by antithrombin III. Arch Biochem Biophvs 1978;185:165-73.
33. Magness RR, Gant NF. Control of vascular reactivity in pregnancy: the basis for therapeutic approaches to prevent pregnancy-induced hypertension. Semin Perinatol 1994;18:45-69.
34. Albertini R, Seino M, Scicli AG, Carretero OA. Uteroplacental renin in regulation of blood pressure in the pregnant rabbit. Am J Physiol 1980;239:H266-71.
35. Boura ALA, Walters WAW, Read MA, Leitch IM. Autacoids and control of human placental blood flow. Clin Exp Pharmacol Physiol 1994;21:737-48.
36. White RP, Robertson JT. Role of plasmin, thrombin and antithrombin III as etiologic factors in delayed cerebral vasospasm. Neurosurgery 1985;16:27-35.
37. White RP. Comparison of inhibitory effects of antithrombin III, α2-macroglobin, and thrombin in human basilar arteries: relevance to cerebral vasospasm. J Cereb Blood Flow Metab 1987;00:68-73.
38. Kerr MB, Marshall K, Senior J. The role of thromboxane in the uterotrophic response in the gravid normotensive and spontaneously hypertensive rat. J Endocrinol 1992;135:257-61.
39. Chemtob S, Potvin W, Varma DR. Selective increase in placental blood flow by atrial natriuretic peptide in hypertensive rats. Am J Obstet Gynecol 1989;160:477-9.
40. Grünewald C, Nisell H, Jansson T, Kublickas M, Thornström S, Nylund L. Possible improvement in uteroplacental blood flow during atrial natriuretic peptide infusion in preeclampsia. Obstet Gynecol 1994;84:235-9.
41. Covi G, Minuz P, Zanarotto R, Marcolongo A, Paluani F, Lechi A. Systemic and uteroplacental hemodynamics and the prostaglandin system in pregnancy-induced hypertension and normal pregnancy. Hypertens Pregnancy 1994;13:273-83.
42. Horie S, Ishii H, Kazama M. Heparin-like glycosaminoglycan is a receptor for antithrombin III-dependent but not for thrombin-dependent prostacyclin production in human endothelial cells. Thromb Res 1990;59:895-904.
43. Laposata M, Dovnarsky DK, Shin HS. Thrombin-induced gap formation in confluent endothelial cell monolayers in vitro. Blood 1983;62:549-56.
44. Draijer R, Atsma DE, van der Laarse A, van Hinsberg VWM. cGMP and nitric oxide modulate thrombin-induced endothelial permeability: regulation via different pathways in human aortic and umbilical vein endothelial cells. Circ Res 1995;76:199-208.
45. Easterling TR, Benedetti TJ. Preeclampsia: a hyperdynamic disease model. Am J Obstet Gynecol 1989;160:1447-53.